Pfizer and BioNTech announce plan to expand Covid-19 vaccine trial
Pfizer and BioNTech are moving to enlarge the Phase 3 trial of their Covid-19 vaccine by 50%, which could allow the companies to collect more safety and efficacy data and to increase the diversity of the study’s participants.
The companies said in a press release that they would increase the size of the study to 44,000 participants, up from an initial recruitment goal of 30,000 individuals.
Read Original Article: Pfizer and BioNTech announce plan to expand Covid-19 vaccine trial »
